Our Commitment
As a portfolio company of Paragon Biosciences, Emalex is unceasing in its pursuit to improve the lives of people living with central nervous system (CNS) disorders through meaningful scientific breakthroughs.
Leadership
Our leadership team is comprised of remarkable professionals who are passionate about innovative solutions that improve the lives of people living with chronic central nervous system conditions.
Emalex Founder and Chairman
Corporate
Eric Messner
CEO
Paul Reinfelds, J.D., Ph.D.
Senior Vice President of Legal Affairs and General Counsel
Ken Borgerding, J.D.
Vice President, Corporate Compliance, Chief Compliance Officer and Corporate Counsel
Clinical
Frederick Munschauer, M.D., MSc., FAAN
Chief Medical Officer, Neurology and
Senior Vice President, Medical and
Scientific Affairs
Sarah Atkinson, M.D.
Vice President, Clinical Development
Trish Rice
Vice President, Biostatistics and Data Management
David Kim
Associate Vice President, Clinical Operations
Meredith M. Miller
Senior Director, Clinical Operations
Regulatory
Commercial
David Knouft
Vice President, Market Access & Patient Services
Brent Paul
Vice President, Marketing & Commercial Operations
Manufacturing
Jay White, Ph.D.
Vice President, Chemistry, Manufacturing and Controls (CMC)
Christine H. Soulje, Ph.D.
Senior Director, Product Development
Christopher Wilson
Senior Director, Drug Product Development
Quality Assurance
Med Affairs
George Karkanias, Ph.D., MBA, MSc.
Vice President, Global Head of Medical and Scientific Affairs
John Flatt, M.D.
Senior Medical Director, Medical Affairs
Tracy Durgin, Pharm.D.
Senior Director, Medical Science Liaisons
Lydia Shenouda, Pharm.D.
Senior Director, Medical & Scientific Affairs
Joy Schleyer
Senior Director, Medical Affairs Operations